Grant McArthur

Grant McArthur

UNVERIFIED PROFILE

Are you Grant McArthur?   Register this Author

Register author
Grant McArthur

Grant McArthur

Publications by authors named "Grant McArthur"

Are you Grant McArthur?   Register this Author

100Publications

5734Reads

7Profile Views

High-resolution MRI demonstrates that more than ninety percent of small intracranial melanoma metastases develop in close relationship to the leptomeninges.

Neuro Oncol 2019 Sep 9. Epub 2019 Sep 9.

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz171DOI Listing
September 2019

Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma.

JAMA Dermatol 2019 Sep 11. Epub 2019 Sep 11.

School of Public Health and Preventive Medicine, Monash University, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2019.2658DOI Listing
September 2019

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 Sep 28. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
September 2019

A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response.

J Invest Dermatol 2019 Sep 30. Epub 2019 Sep 30.

Victorian Melanoma Service, Alfred Hospital; School of Public Health and Preventive Medicine, Monash University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2019.07.725DOI Listing
September 2019

Molecular Genomic Profiling of Melanocytic Nevi.

J Invest Dermatol 2019 Aug 14;139(8):1762-1768. Epub 2019 Feb 14.

Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X193011
Publisher Site
http://dx.doi.org/10.1016/j.jid.2018.12.033DOI Listing
August 2019

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

J Mol Diagn 2019 May 5;21(3):418-426. Epub 2019 Feb 5.

Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15251578183023
Publisher Site
http://dx.doi.org/10.1016/j.jmoldx.2018.12.001DOI Listing
May 2019

Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.

Health Sci Rep 2019 Mar 1;2(3):e115. Epub 2019 Feb 1.

Department of Cancer Medicine, Melbourne Peter MacCallum Cancer Centre Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hsr2.115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427059PMC
March 2019

Concordance of somatic mutational profile in multiple primary melanomas.

Pigment Cell Melanoma Res 2018 09 15;31(5):592-603. Epub 2018 Apr 15.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12702DOI Listing
September 2018

A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.

Cancer Chemother Pharmacol 2018 09 9;82(3):493-503. Epub 2018 Jul 9.

The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3634-4DOI Listing
September 2018

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply.

Lancet Oncol 2018 08;19(8):e367

Disciplines of Medical Oncology, Melanoma Institute Australia, University of Sydney, Sydney, NSW 2065, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30508-4DOI Listing
August 2018

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Lancet Oncol 2018 05 27;19(5):672-681. Epub 2018 Mar 27.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; Medical, Dental and Health Sciences, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30139-6DOI Listing
May 2018

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.

Br J Cancer 2018 05 14;118(10):1289-1295. Epub 2018 May 14.

Victorian Melanoma Service, Alfred Hospital, Melbourne, VIC, 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0088-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959932PMC
May 2018

New Era in the Management of Melanoma Brain Metastases.

Am Soc Clin Oncol Educ Book 2018 May;38:741-750

From The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, Paris, France; Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200819DOI Listing
May 2018

Optimizing Amplification of the GC-Rich Promoter Region Using 7-Deaza-dGTP for Droplet Digital PCR Quantification of Promoter Mutations.

Clin Chem 2018 04 30;64(4):745-747. Epub 2018 Jan 30.

Department of Pathology, University of Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2017.284257DOI Listing
April 2018

Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma.

Asia Pac J Clin Oncol 2017 Dec 29;13(6):385-390. Epub 2017 Jun 29.

Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.12702
Publisher Site
http://dx.doi.org/10.1111/ajco.12702DOI Listing
December 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.

Br J Cancer 2017 Sep 8;117(7):1026-1035. Epub 2017 Aug 8.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Victoria 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625668PMC
September 2017

The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.

Eur J Nucl Med Mol Imaging 2017 Aug 7;44(Suppl 1):67-77. Epub 2017 Apr 7.

The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-017-3691-7DOI Listing
August 2017

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?

J Transl Med 2017 08 8;15(1):173. Epub 2017 Aug 8.

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-017-1278-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549368PMC
August 2017

The best treatments to use after checkpoint inhibition in melanoma.

Authors:
Grant McArthur

Clin Adv Hematol Oncol 2017 Apr;15(4):242-245

Melanoma and Skin Service and Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
April 2017

Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.

BMJ Case Rep 2016 Nov 23;2016. Epub 2016 Nov 23.

Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2016-217454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174822PMC
November 2016

Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.

Int J Cancer 2016 Jul 10;139(1):194-204. Epub 2016 Mar 10.

Peter MacCallum Cancer Centre, Translational Research Laboratory, East Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30056DOI Listing
July 2016

Cell Cycle Regulation and Melanoma.

Curr Oncol Rep 2016 06;18(6):34

Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-016-0524-yDOI Listing
June 2016

Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma.

Pharmacol Res 2016 05 26;107:42-47. Epub 2016 Feb 26.

Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, Peter MacCallum Cancer Centre, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Translational Research Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Australia; Department of Pathology, University of Melbourne, Australia; Department of Medicine, St. Vincent's Hospital, University of Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2016.02.009DOI Listing
May 2016

Integration of Immuno-Oncology and Palliative Care.

J Clin Oncol 2016 05 29;34(13):1561-2. Epub 2016 Feb 29.

Peter MacCallum Cancer Centre, East Melbourne; and University of Melbourne, Parkville, Victoria, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.4146DOI Listing
May 2016

Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.

J Clin Oncol 2016 Apr 13;34(12):e104-6. Epub 2014 Oct 13.

Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/10/10/JCO.2013.51
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.51.3572
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.51.3572DOI Listing
April 2016

Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.

Curr Opin Immunol 2016 Apr 5;39:30-8. Epub 2016 Jan 5.

Department of Cancer Medicine, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2015.12.006DOI Listing
April 2016

Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma.

Pigment Cell Melanoma Res 2016 Mar 17;29(2):222-8. Epub 2016 Jan 17.

Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12450DOI Listing
March 2016

BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.

J Natl Compr Canc Netw 2016 03 8;14(3):249-54. Epub 2016 Mar 8.

Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0030DOI Listing
March 2016

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

Cancer Discov 2016 Jan 21;6(1):59-70. Epub 2015 Oct 21.

Division of Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0673DOI Listing
January 2016

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

Eur J Cancer 2016 Jan 17;53:125-34. Epub 2015 Dec 17.

Center for Dermatooncology, Department of Dermatology, University Tuebingen, 72074 Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.09.013DOI Listing
January 2016

CDK4 inhibitors an emerging strategy for the treatment of melanoma.

Melanoma Manag 2015 Aug 10;2(3):255-266. Epub 2015 Aug 10.

Department of Cancer Medicine, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094902PMC
August 2015

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet.

Authors:
Grant A McArthur

Front Oncol 2015 17;5:161. Epub 2015 Jul 17.

Department of Cancer Medicine, Peter MacCallum Cancer Centre , East Melbourne, VIC , Australia ; Department of Pathology, University of Melbourne , Parkville, VIC , Australia ; Department of Medicine, St Vincent's Hospital, University of Melbourne , Fitzroy, VIC , Australia ; Sir Peter MacCallum Department of Oncology, University of Melbourne , East Melbourne, VIC , Australia ; Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, Peter MacCallum Cancer Centre , East Melbourne, VIC , Australia ; Translational Research Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer Centre , East Melbourne, VIC , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505146PMC
August 2015

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Sci Signal 2015 Aug 18;8(390):ra82. Epub 2015 Aug 18.

Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne, Victoria 3002, Australia. Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria 3010, Australia. Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria 3010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aab1111DOI Listing
August 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med 2015 Jul 31;373(1):23-34. Epub 2015 May 31.

From the Department of Medical Oncology, Royal Marsden Hospital, London (J.L.), and South West Wales Cancer Institute, Singleton Hospital, Swansea (J.W.) - both in the United Kingdom; Melanoma Oncology Unit, Veneto Region Oncology Research Institute, Padua (V.C.-S.), Oncology of Melanoma Unit, European Institute of Oncology, Milan (P.F.F.), University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; Division of Medical Oncology, University of Colorado, Denver, Denver (R.G.); Aix-Marseille University, Hôpital de La Timone, Assitance Publique-Hôpitaux de Marseille, Marseille (J.J.G.), and Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.) - both in France; Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor (C.D.L.); Department of Dermatology, University of Essen, Essen, Germany (D.S.); University of Zürich Hospital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB, Canada (M. Smylie); Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland (P.R.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), and Westmead and Blacktown Hospitals (M.S.C.) and Melanoma Institute Australia (M.S.C., G.V.L.), University of Sydney, and the Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (G.A.M.) - all in Australia; Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam (J.B.H.); Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid (I.M.-R.); Ludwig Center, Memorial Sloan Kettering Cancer Center (M.K.C., M.A.P., J.D.W.) and Weill Cornell Medical College (M.K.C., M.A.P., J.D.W.) - both in New York; Huntsman Cancer Institute, University of Utah, Salt Lake City (K.G.); Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University Sc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1504030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905PMC
July 2015

The genomic landscape of phaeochromocytoma.

J Pathol 2015 May 2;236(1):78-89. Epub 2015 Feb 2.

The Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; The Department of Pathology, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4503DOI Listing
May 2015

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

Eur J Cancer 2015 May 19;51(7):852-60. Epub 2015 Mar 19.

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.02.015DOI Listing
May 2015

Adjuvant immunotherapy for cancer: the next step.

Lancet Oncol 2015 May 31;16(5):478-80. Epub 2015 Mar 31.

Divisions of Cancer Medicine and Research, Peter MacCallum Cancer Centre, University of Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451570162
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)70162-2DOI Listing
May 2015

Melanoma.

Nat Rev Dis Primers 2015 04 23;1:15003. Epub 2015 Apr 23.

Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrdp.2015.3DOI Listing
April 2015

Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.

FASEB J 2015 Apr 30;29(4):1426-34. Epub 2014 Dec 30.

*Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia; University of Melbourne Department of Medicine, Austin Health, Heidelberg, Victoria, Australia; Translational Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; St. Vincent's Institute of Medical Research and University of Melbourne Department of Medicine, St. Vincent's Hospital, Fitzroy, Victoria, Australia; Bone Research Program, ANZAC Research Institute, The University of Sydney, Sydney, New South Wales, Australia; Differentiation and Transcription Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; **Department of Pathology, University of Melbourne, Parkville, Victoria, Australia; Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; and University of Melbourne Department of Surgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia

View Article

Download full-text PDF

Source
http://www.fasebj.org/content/29/4/1426.full.pdf
Web Search
http://www.fasebj.org/cgi/doi/10.1096/fj.14-262782
Publisher Site
http://dx.doi.org/10.1096/fj.14-262782DOI Listing
April 2015

Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.

Cancer Immunol Immunother 2015 Apr 7;64(4):507-18. Epub 2015 Feb 7.

Ludwig Institute for Cancer Research (Melbourne-Austin Branch), 147-163 Studley Road, Heidelberg, VIC, 3084, Australia,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-015-1656-xDOI Listing
April 2015

Radiotherapy complements immune checkpoint blockade.

Cancer Cell 2015 Apr;27(4):437-8

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, Herston, QLD 4006, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.03.015DOI Listing
April 2015

Cell cycle control as a promising target in melanoma.

Curr Opin Oncol 2015 Mar;27(2):141-50

aDepartment of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne bDepartment of Pathology, University of Melbourne, Parkville cDepartment of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy dMolecular Oncology Laboratory, Oncogenic Signalling and Growth Control Program eTranslational Research Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000159DOI Listing
March 2015

Phenotype switching in melanoma: implications for progression and therapy.

Front Oncol 2015 13;5:31. Epub 2015 Feb 13.

Oncogenic Signaling and Growth Control Program, Research Division, Peter MacCallum Cancer Center , East Melbourne, VIC , Australia ; Sir Peter MacCallum Department of Oncology, The University of Melbourne , East Melbourne, VIC , Australia ; Department of Pathology, The University of Melbourne , East Melbourne, VIC , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327420PMC
March 2015

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.

Oncotarget 2015 Jan;6(2):1115-27

Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359221PMC
http://dx.doi.org/10.18632/oncotarget.2747DOI Listing
January 2015

Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.

Pigment Cell Melanoma Res 2014 Nov 4;27(6):1117-25. Epub 2014 Aug 4.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic., Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12295DOI Listing
November 2014

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

N Engl J Med 2014 Nov 29;371(20):1867-76. Epub 2014 Sep 29.

From Royal Marsden Hospital, London (J.L.); Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Azienda Ospedaliera Universitaria Senese, Siena (M. Maio), and Papa Giovanni XXIII Hospital, Bergamo (M. Mandalà) - all in Italy; Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.), Centre Hospitalier Lyon Sud, Pierre-Bénite (L.T.), and Hôpital Saint André, Bordeaux (C.D.) - all in France; Princess Alexandra Hospital, Woolloongabba, QLD (V.A.), and Peter MacCallum Cancer Centre, Melbourne, VIC (G.A.M.) - both in Australia; National Institute of Oncology, Budapest, Hungary (G.L.); N.N. Blokhin Russian Cancer Research Center, Moscow (L.D.), and Moscow City Oncology Hospital 62, Krasnogorsk (D.S.) - both in Russia; Hospital Universitario Virgen Macarena, Seville, Spain (L.C.-M.); University of Tübingen, Tübingen, Germany (C.G.); Genentech, South San Francisco, CA (M.A.S., I.C., N.C., S.P.H.); and Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles (A.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408868DOI Listing
November 2014

Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.

Am J Ophthalmol 2014 Oct 15;158(4):831-837.e2. Epub 2014 Jul 15.

Department of Medicine, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2014.07.003DOI Listing
October 2014

Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.

Med J Aust 2014 Jul;201(1):49-53

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5694/mja13.10448DOI Listing
July 2014